AbbVie (ABBV) Non-Current Deferred Tax Liability (2012 - 2026)
AbbVie (ABBV) posted quarterly Non-Current Deferred Tax Liability of $2.3 billion for Q1 2026, down 9.68% year-over-year from $2.6 billion in Q1 2025, and down 2.39% quarter-over-quarter from $2.4 billion in Q4 2025.
AbbVie (ABBV) Non-Current Deferred Tax Liability (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Non-Current Deferred Tax Liability for 15 consecutive years, with $2.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 9.68% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 9.68% YoY), while the FY2025 annual figure was $2.4 billion, down 7.37% from the prior year.
- Non-Current Deferred Tax Liability eased to $2.3 billion in Q1 2026 per ABBV's latest filing, from $2.4 billion in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $2.8 billion in Q1 2022 and bottomed at $2.0 billion in Q4 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $2.4 billion across 5 years, with a median of $2.4 billion in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability tumbled 45.25% — and 2024, when it jumped 34.49%.
- AbbVie's Non-Current Deferred Tax Liability stood at $2.2 billion in 2022, then decreased by 10.87% to $2.0 billion in 2023, then soared by 32.12% to $2.6 billion in 2024, then fell by 7.37% to $2.4 billion in 2025, then decreased by 2.39% to $2.3 billion in 2026.
- Business Quant data shows ABBV's Non-Current Deferred Tax Liability at $2.3 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.28 Bn |
| Jun 30, 2026 | 2.28 Bn |
| Mar 31, 2026 | 2.33 Bn |
| Mar 31, 2026 | 2.33 Bn |
| Dec 31, 2025 | 2.39 Bn |
| Dec 31, 2025 | 2.39 Bn |
| Sep 30, 2025 | 2.48 Bn |
| Sep 30, 2025 | 2.48 Bn |
| Jun 30, 2025 | 2.55 Bn |
| Jun 30, 2025 | 2.55 Bn |
| Mar 31, 2025 | 2.58 Bn |
| Mar 31, 2025 | 2.58 Bn |
| Dec 31, 2024 | 2.58 Bn |
| Dec 31, 2024 | 2.58 Bn |
| Sep 30, 2024 | 2.75 Bn |
| Sep 30, 2024 | 2.75 Bn |
| Jun 30, 2024 | 2.73 Bn |
| Jun 30, 2024 | 2.73 Bn |
| Mar 31, 2024 | 2.72 Bn |
| Mar 31, 2024 | 2.72 Bn |